Pulmonary Function Testing (PFT) serves as a crucial tool in the diagnosis, management, and monitoring of respiratory diseases. It provides objective, quantifiable data about lung function, aiding clinicians in making informed decisions regarding patient care. This article aims to elucidate the interpretation of PFTs for healthcare professionals.
Spirometry forms the cornerstone of PFT. It measures the volume of air that can be inhaled or exhaled in a specific time frame. Key parameters include Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and their ratio (FEV1/FVC). A reduced FEV1/FVC ratio signifies obstructive lung disease, while a reduced FVC with a normal FEV1/FVC ratio suggests restrictive lung disease.
Besides spirometry, measuring lung volumes provides additional insights into lung mechanics. Total Lung Capacity (TLC), Residual Volume (RV), and Functional Residual Capacity (FRC) are the primary measures. Elevated RV and FRC indicate air trapping, a hallmark of obstructive diseases. A reduced TLC, on the other hand, is indicative of restrictive pathology.
The DLCO test measures the lung's ability to transfer gas from inhaled air to the red blood cells in pulmonary capillaries. A decreased DLCO could signify interstitial lung disease, pulmonary vascular disease, or emphysema. It's crucial to interpret DLCO in conjunction with spirometry and lung volumes for accurate diagnosis.
Interpreting PFTs is a complex process requiring a comprehensive understanding of respiratory physiology and pathology. However, with a systematic approach to spirometry, lung volumes, and DLCO, healthcare professionals can effectively utilize PFTs to diagnose, manage, and monitor a wide range of respiratory conditions. Continual learning and practice are key to mastering this essential clinical skill.
1.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
2.
Health researchers discuss Medicaid cancer screening trends, best practices
3.
Taking Charge of Your Cancer Journey.
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Breaking Down Leukocytoclastic Vasculitis: Causes, Symptoms and Treatment
3.
Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More
4.
A Review on Genetic Predispositions and Clinical Advancements of Multiple Myeloma Cancer
5.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
Navigating the Complexities of Ph Negative ALL - Part II
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation